Phantoms for spectral CT experiments

The Food and Drug Administration is forecasting a requirement for the procurement of phantoms designed for spectral CT experiments. These phantoms must feature a cylindrical geometry and include specific inserts composed of iodine and calcium hydroxyapatite, set against uniform background materials to facilitate precise spectral CT testing. This opportunity is managed by the Food and Drug Administration, with the Cdrh Acquisition Liaison serving as the primary program point of contact. While a specific contracting officer has not yet been named, interested parties can find further information through the official HHS industry opportunity forecast portal.